Peptide data sheet
Petrelintide
GLP-1 · ZP8396 · ZP-8396
Verdict
promisinghuman evidence limited to early-phase trials
By MrPepTalks Editorial
Reviewed for scientific accuracy · research information, not medical advice
Last updated Reviewed
Quick answer
Petrelintide is an investigational long-acting amylin analog from Zealand Pharma, studied as a once-weekly injection for weight management. Two published Phase 1 trials reported a body-weight reduction of up to 8.6% over 16 weeks and a half-life of roughly 10 days. Gastrointestinal events were mostly mild, though one participant left because of them. The Phase 2 trial, ZUPREME-1, enrolled 493 people and has finished, but nothing is posted on the registry and no peer-reviewed report has appeared, so the strongest public evidence is still Phase 1. Petrelintide is not FDA-approved for any use and is not sold as a medicine or a supplement.
- Class
- Long-acting amylin analog (investigational)
- Half-life
- About 10 days, reported in Phase 1 trials
- FDA status
- Investigational: not approved for any use
Which form actually works?
Injectable (once-weekly)
Promising
The only form in the published clinical programme; petrelintide is given as a weekly injection in trials and is not available as a consumer product.
Third-Party Testing & Certificate of Analysis (COA)
A certificate of analysis (COA) is a lab document that reports what a specific batch of material actually contains. Reputable research suppliers publish one for every batch, tied to a lot number you can match against the vial you received.
- HPLC — purity
- High-performance liquid chromatography reports purity as a percentage: how much of the sample is the intended compound rather than impurities.
- Mass spectrometry (MS) — identity
- Mass spectrometry confirms identity by measuring the sample's molecular mass, so it matches the peptide the label names.
It also matters who ran the test. In-house results come from the seller's own lab; an independent third-party lab has no stake in the result, so its COA generally carries more weight. Look for a named testing laboratory, a batch or lot number, and a test date that lines up with the vial in hand.
New to reading one? This guide walks through a COA line by line: how to read a peptide COA.
Sources
- Brændholt Olsen M, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026. PMID 42017294.
- NCT06662539: A Randomized, Double-blind, Phase 2, Dose-finding Trial of Once Weekly Petrelintide Compared With Placebo in Participants With Obesity or Overweight With Weight Related Comorbidities (ZUPREME-1). ClinicalTrials.gov.
- NCT06926842: Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME-2). ClinicalTrials.gov.
- Fischer Munch H, et al. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem. 2025. PMID 41217931.
- Bailey CJ, Flatt PR, Conlon JM. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. 2026. PMID 41747885.
- Alhazmi A, le Roux CW. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab. 2026. PMID 42452898.
- ClinicalTrials.gov registry search for petrelintide interventional studies (checked 2026-07-26; the highest registered phase is Phase 2).
- PubChem Compound Summary for CID 172915807, Petrelintide. National Library of Medicine (US), National Center for Biotechnology Information.